Latest Intelligence on Therapy Area in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA meeting 2009: Shire to maintain market leading status in ADHD

At the American Psychiatric Association's annual meeting, British pharmaceutical firm Shire presented data on its diverse attention deficit hyperactivity disorder portfolio, covering three key products. Through continued astute portfolio management, Datamonitor forecasts Shire to remain the market leader with a 40% share of the ADHD sector by 2017.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer

Established drugs such as Cymbalta and Lyrica will serve to restrict uptake of the most recent entrant to the fibromyalgia market, Savella. Accordingly, data presented at this year's American Pain Society Annual Meeting indicate that Savella's marketing companies are endeavoring to differentiate the product from its key competitors in order to maintain uptake and drive sales.

Published By Datamonitor
17 May 2010
Expert View
Expert View

APS 2010: opioid safety and tolerability analyses take center stage

Opioid-related announcements at this year's American Pain Society meeting reflected the FDA's current focus on instituting regulations to increase the safety of this class. Johnson & Johnson used the meeting to present long-term data for its advanced candidate tapentadol, while King Pharmaceuticals demonstrated a taper procedure to be successful in minimizing withdrawal in patients taking Embeda.

Published By Datamonitor
17 May 2010
Expert View
Expert View

ASCO 2010: first-line chronic myeloid leukemia becomes next battleground for Sprycel and Tasigna

Datamonitor attended this year's meeting of the American Society of Clinical Oncology, where Bristol-Myers Squibb and Novartis revealed that their respective second-generation kinase inhibitors both surpass current standard of care Gleevec in first-line chronic myeloid leukemia. With little differentiating the two agents, a fierce marketing war will determine which becomes the new market leader.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

ASCO 2010: ipilimumab achieves breakthrough in 'long dark tunnel' of metastatic melanoma

At this year's American Society of Clinical Oncology meeting, Bristol-Myers Squibb presented data for its monoclonal antibody ipilimumab in metastatic melanoma. Research and development in this area has been underwhelming over the past few years and, despite its high rate of adverse events, ipilimumab represents a breakthrough in the treatment of metastatic melanoma.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

ASCO meeting 2009: current blockbusters advance standard care in new indications

Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

ASCO meeting 2009: is maintenance the new paradigm for the treatment of NSCLC?

The numerous studies of maintenance therapy which were presented at this year's American Society of Clinical Oncology meeting suggest that pharmaceutical groups are looking to tap into a new treatment setting in NSCLC. However, maintenance therapy is unlikely to become a new paradigm unless biomarker-driven studies help identify the patients which derive the greatest benefit from this treatment.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

ASH 2009: competition between Velcade and Revlimid intensifies in multiple myeloma

Datamonitor attended this year's American Society of Hematology annual meeting in New Orleans, focusing on key developments in hematological malignancies. While recent trial results are likely to support new applications for Velcade and Revlimid in first-line multiple myeloma, the data also suggest that the future of treatment may actually be a combination of the two.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML

At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely that the drug will achieve the same market penetration as Gleevec in newly diagnosed patients due to fierce competition from Sprycel.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

Asthma/COPD innovation scarce among top pharmaceutical companies

Many asthma and chronic obstructive pulmonary disease patients are now being treated with inhaled corticosteroid/long-acting beta2-agonist fixed-dose combinations, a lifecycle management strategy generating high sales from a relatively low investment. However, the lack of truly novel drug targets means that other unmet needs in asthma and COPD are being overlooked by the leading players.

Published By Datamonitor
26 Sep 2007

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.